Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing etripamil, a nasal spray therapy for cardiovascular conditions. The company is preparing for potential U.S. commercialization of CARDAMYST for paroxysmal supraventricular tachycardia (PSVT) while also evaluating additional indications such as atrial fibrillation with rapid ventricular rate.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaEtripamil-based nasal spray therapy being developed and prepared for commercialization.
Additional indications and future cardiovascular uses for etripamil.
Potential milestone-based license revenue and regional commercialization rights.
Asiakkaat
Milestone does not yet sell approved products, so its current 'customers' are mainly regulators, clinical trial sites, CROs, and potential commercial partners rather than end patients. If approved, the primary buyers would be U.S. physicians, hospitals, and patients using CARDAMYST for PSVT, with payers and pharmacy channels influencing access and uptake.
FDA, CROs, CMOs, and trial sites that enable development, review, and approval of etripamil.
Cardiology and emergency-care prescribers treating PSVT patients with a potential self-administered nasal therapy.
Insurers, PBMs, and pharmacy channels that will influence reimbursement and adoption after launch.
Companies that may commercialize or develop etripamil outside the United States.
Strategia
Milestone's strategy is centered on completing development and regulatory remediation for etripamil, then launching CARDAMYST in the United States through a direct sales model. The company is also preserving optionality through ex-U.S. partnering and by seeking additional product candidates through licensing.
Approval is the key gating event for first product revenue and commercial entry.
A direct commercial model is intended to capture value if approval is secured.
A broader label could increase the product's addressable market and lifecycle value.
Partnerships can extend geographic reach and reduce capital needs outside the U.S.
Maantiede
Milestone is headquartered in the United States and plans to commercialize etripamil directly in the U.S. if approved. Outside the United States, it is considering collaboration-based strategies, while the report also notes potential licensing rights outside Greater China, indicating a broader but partner-led international footprint.
Riskit
Milestone is highly dependent on a single asset, etripamil, so regulatory setbacks or clinical failure would materially impair the business. The company also faces funding risk because it has no product revenue yet, continues to burn cash, and may need additional capital to support development and launch activities.
- Regulatory approval failure or delay for etripamilVaikutus: KriittinenTodennäköisyys: Korkea
The company has only one product candidate and revenue depends on FDA approval.
Kohdistuu: CARDAMYST / PSVT launch
- Clinical development uncertaintyVaikutus: KorkeaTodennäköisyys: Korkea
Trial outcomes, timelines, and costs can differ materially from expectations.
Kohdistuu - Capital shortfall and dilutionVaikutus: Korkea
The company continues to incur operating losses and has limited cash relative to launch and development needs.
Kohdistuu: R&D and commercialization funding
- Trade and supply-chain disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company relies on third-party suppliers in several countries outside the U.S.
Kohdistuu: Outsourced development and manufacturing network
- Commercial launch execution riskVaikutus: Keskitaso
A direct U.S. launch requires infrastructure, personnel, and payer access capabilities.
Kohdistuu: U.S. commercialization
Kirjanpito
Harkinnanvaraiset erätManagement estimates work completed under CRO, CMO, and site contracts, affecting R&D expense timing.
Vaikutus: Can shift expenses between quarters and change reported operating loss
Option fair value is estimated using Black-Scholes inputs, which affect G&A and R&D expense.
Vaikutus: Non-cash expense can materially affect reported losses
Revenue from the Corxel agreement is recognized only when contractual milestones are achieved.
Vaikutus: Revenue may be lumpy and unpredictable
Commercial build-out costs may rise quickly around approval and launch preparation.
Vaikutus: Quarterly operating expense volatility
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
KalVista Pharmaceuticals, Inc.
Pharmaceutical Preparations
KalVista Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing oral therapies for hereditary angioedema (HAE).
Milestone Scientific, Inc
MLSS · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Tenax Therapeutics, Inc
TENX · Pharmaceutical Preparations
Cytokinetics, Incorporated
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
Päivitetty: 24.9.2026